Get started
Author

Martine Bomb

Observed names: M Bomb (13648609), M. Bomb
OpenAlex ID: A5025028372
30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study
2016 · Michael Wallington, Emma B Saxon, et al. · The Lancet Oncology · 182
PDF
Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset
2019 · Chloe J Bright, Sarah Lawton, et al. · International Journal of Epidemiology · 115
CD6 Regulates T-Cell Responses through Activation-Dependent Recruitment of the Positive Regulator SLP-76
2006 · Namir J. Hassan, Stephen J. Simmonds, et al. · Molecular and Cellular Biology · 104
The International Cancer Benchmarking Partnership: An international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom
2013 · John Butler, Catherine Foot, et al. · Health Policy · 102
PDF
An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation
2016 · David Weller, Peter Vedsted, et al. · BMJ Open · 57
PDF
NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants
2025 · Charles Swanton, Velicia Bachtiar, et al. · Clinical Trials · 8
Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study
2018 · N.M.L. Battisti, M. Wallington, et al. · Annals of Oncology · 8
Corrigendum to: Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) Dataset
2019 · Chloe J Bright, Sarah Lawton, et al. · International Journal of Epidemiology · 5
PDF
Rapid Analysis of Outcomes Using the Systemic Anti-Cancer Therapy (SACT) Dataset
2017 · R. Pathak, M. Wallington, et al. · Clinical Oncology · 4
The impact of the COVID-19 pandemic on the use of systemic therapy for patients diagnosed with cancer in England: A population-based study with a focus on breast and lung cancer
2025 · Laura Webster, Sarah Lawton, et al. · Cancer Epidemiology · 3
Second Correction for Hassan et al., “CD6 Regulates T-Cell Responses through Activation-Dependent Recruitment of the Positive Regulator SLP-76”
2019 · Namir J. Hassan, Stephen J. Simmonds, et al. · Molecular and Cellular Biology · 3
1239P NHS-Galleri trial enrolment approaches and participant sociodemographic diversity
2023 · C. Swanton, V. Bachtiar, et al. · Annals of Oncology · 1
PDF
Early breast cancer in England: Evidence into practice
2019 · R. Smittenaar, M. Bomb, et al. · Journal of Cancer Policy · 1
Accelerated cancer registration from the National Disease Registration Service to support the NHS-Galleri trial
2026 · Charlotte Eversfield, Natalia Petersen, et al. · medRxiv
PDF
Abstract P2-12-03: The effect of Abemaciclib plus fulvestrant on overall survival in hormone-receptor positive, HER2-negative breast cancer that progressed on endocrine therapy – Comparing Real-World outcomes in England to MONARCH 2
2025 · Emma Kipps, Jack Anderson, et al. · Clinical Cancer Research
P78.01 Nivolumab in Second Line Non-Small Cell Lung Cancer – Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057
2021 · S. Popat, N. Tanna, et al. · Journal of Thoracic Oncology
PDF
Data resource description: Systemic Anti-Cancer Therapy (SACT) Dataset
2019 · Chloe Bright, Sarah Lawton, et al. · International Journal for Population Data Science
PDF
Explaining variation in cancer outcomes between eleven jurisdictions in the International Cancer Benchmarking Partnership: a primary care survey
2014 · P Rose (13638211), P Vedsted (13323786), et al. · Open Research Exeter (University of Exeter)
Works count: 18
Citation count: 593
H-index: 7
I10-index: 5
Year
Topic
Type